Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises FJ Dynamics on its acquisition of Sveaverken Svea Agri
Mandate

Vinge advises FJ Dynamics on its acquisition of Sveaverken Svea Agri

October 16, 2019 M&A

Vinge has advised FJ Dynamics, a leading global robotic company in the agricultural sector, in connection with its acquisition of Sveaverken Svea Agri.

Sveaverken Svea Agri is an animal farming company with over 100 years history with headquarters in Sweden. With the acquisition, FJ Dynamics will empower traditional animal farming with leading intelligent robotics and create significant value and synergy to benefit more customers around the world.

Vinge’s team consisted of, among others, Ulrich Ziche, Qun Gu, Desirée Sjöblom and Jesper Lindvall (M&A and commercial agreements), Morgan Hallén and Daniel Lennartsson Anderås (Banking, financing and restructuring), Sophia Holm (Employment) and Anne Wijkman (Real Estate and lease agreements).
 

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026